Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells

作者：Chenxiao Qiao, Yipeng Xu, Yedie He, Zhijian Cai, Hua Wang · 发表于：Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 年份：2024 · DOI：10.32604/or.2024.055746 · 被引用次数：10 · 研究领域：Virus-based gene therapy research、Cancer Research and Treatments、Phagocytosis and Immune Regulation

Objective: To investigate the anti-tumor effects of an E1B55KD-deleted oncolytic adenovirus, H101, in combination with a humanized anti-PD-1 (Programmed cell death protein 1) monoclonal antibody, Camrelizumab. Methods: mice subcutaneous (S.C.) tumor model, established with human glioblastoma of unknown origin cell line U87-MG, and human bladder cancer cell line T24 and YTS-1. The mechanism by which H101 induced anti-tumor immunity were also investigated. Results: T cells. Conclusion: The combination of H101 with PD-1 blockade exhibits potential as a novel strategy for the treatment of cancer.